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The landmark publication by the National Research Council
putting forward a vision of a toxicology for the 21st century in
2007 has created an atmosphere of departure in our ﬁeld. The
alliances formed, symposia and meetings held and the articles
following are remarkable, indicating that this is an idea whose
time has come. Most of the discussion centers on the technical
opportunities to map pathways of toxicity and the ﬁnancing of the
program. Here, the other part of the work ahead shall be
discussed, that is, the focus is on regulatory implementation once
the technological challenges are managed, but we are well aware
that the technical aspects of what the National Academy of
Science report suggests still need to be addressed: A series of
challenges are put forward which we will face in addition to
ﬁnding a technical solution (and its funding) to set this vision into
practice. This includes the standardization and quality assurance
of novel methodologies, their formal validation, their integration
into test strategies including threshold setting and ﬁnally a global
acceptance and implementation. This will require intense
conceptual steering to have all pieces of the puzzle come together.
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The willingness to accept risks in daily life is diminishing
continuously. The willingness to lessen efforts of safety
evaluations is therefore low. Thus, a generally accepted con-
sensus is that new approaches must not lower the current safety
standards. This leads quickly to a concept, where current
methodologies are considered gold standards, which need to be
met. It is therefore not sufﬁcient to develop new approaches, but
also to show their limitations in comparison to current regimes,
a process normally summarized as validation. However, this
typicallyleadstoastrategywhereoutofthe‘‘patch-work’’ofthe
toxicologicaltool-box,maximallyonepatchisreplacedbyanew
one. This does not really open up for a new general approach.
We might take a different view and ask ourselves, how
regulatory toxicology would be done, if we had to design it from
the scratch. The vision of the NRC committee (Andersen and
Krewski, 2009; National Research Council, 2007) is laying out
such a new design, putting forward a new approach based on
modern technologies and in a more integrated way (Hartung and
Leist,2008;Leistetal.,2008).Thisincludeslikelytheaccumulated
knowledge on pathways of toxicity, modern technologies such as
(human) cell culture, omics technologies (genomics, proteomics,
metabonomics),imageanalysis,high-through-puttesting,insilico
modeling including PBPK (physiology-based pharmaco-, here
moretoxico-,kineticmodeling)andQSAR(quantitativestructure
activityrelationships).Federalagencieshavealreadyjoinedforces
toattemptthis(Collinsetal.,2008).Forthepurposeofthisarticle
let us assume the feasibility of this approach. It is unrealistic to
assume that it will be a one test approach, which does the whole
job—likelyitwillbeanothertestbattery(tool-box).However,itis
the ﬁrst hypothesis put forward that we can only gain if we
construct this new approach from scratch and not only replace or
add new ‘‘patches.’’ We shall explore here, which fundamental
problems remain, and if such a battery of novel tests can be
achieved, independent of the technologies to be applied.
CHALLENGE 1: TESTING STRATEGIES INSTEAD OF
INDIVIDUAL TESTS
Today’s approach to regulatory testing is rather simple: one
problem, one test. Limitations of this approach have been
discussed earlier (Hartung, 2008b) especially when considering
the low prevalence of most hazards (Hoffmann and Hartung,
2005). It is important to note that in vitro tests do not have less
limitations that the in vivo ones (Hartung, 2007b). A toxicology
based on pathways is one which is likely based on various tests,
beitinabattery(i.e.,wherealltestsaredonetoderivetheresults)
or a test strategy (i.e., where tests are done based on interim
decisionpoints).Ourexperienceswiththeﬁrstapproacharepoor
andbad:Combiningtypicallythreemutagenicitytestsinabattery
resulted in a disaster of accumulating false-positives (Kirkland
etal.,2005):only3–20%ofpositiveﬁndingsare real-positives—
hardly an efﬁcient strategy. We therefore need other ways to
combine tests for the different pathways in a different way, but
we have neither a terminology for test strategies nor tools to
compose or validate them.
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When testing for multiple pathways, we will need to correct
our statistics for multiple testing. We have to lower signiﬁcance
levels accordingly or we will run increasingly into false-positive
ﬁndings. Theproponentsof thenew approachassumemore than
a hundred, and less than a thousand such pathways. A lot of
multiple testing...Assuming only 100 pathways, signiﬁcance
levels of p ¼ 0.05 would have to be lowered to 0.006 using the
most common Bonferroni correction. This—likely with sophis-
ticated methods of high inherent variance—will result in an
astronomic number of replicates necessary: For the example of
p ¼ 0.05 and stable noise/signal ratios, a 71-fold increase in
sample size (e.g., number of animals or replicate cellular tests) is
necessary to reach the same level of conﬁdence.
CHALLENGE 3: THRESHOLD SETTING
Where does a relevant effect start? Certainly not where we
can measure a signiﬁcant change. What is measurable depends
only on our detection limits, and in the case of multiendpoint
methods a lot on signal/noise relation and the inevitable
number of false-positive results. If, for example, a toxicoge-
nomics approach is taken, several thousand genes might be
measured and, especially when low thresholds of fold-
induction are used, false-positive events will occur. Even if
real-positive, the questions arising are then, whether this is
signiﬁcant with the given number of replicates, or even more
important, whether this is relevant (notably completely
different questions). Although the former can be tested with
replicate testing and statistics (see, however, problem of
multiple testing), the relevance is more difﬁcult to establish:
The more remote we are in (sub-) cellular pathways, the more
difﬁcult to extrapolate to the overall organism. The NRC vision
document is not really clear here, whether we talk of cells and
their signal transduction pathways or the even more compli-
cated physiological pathways of in dynamic systems with
compensatory mechanisms.
Whatdoesitmeanifapathwayistriggeredbutifaccompanied
by some compensatory ones as well? We deﬁnitively have to
overcome the mentality of ‘‘we see an effect, this is an effect
level.’’ Any method, which assesses only a certain level of the
organism (e.g., the transcriptome when using genomics), will be
questioned whether these changes are translated to the higher
integration levels (proteome, metabolism, physiology). This
argues for systems biology approaches where such consider-
ations are taken into account, but complexity of modeling
increases dramatically, with impacts on standardization, costs,
feasible number of replicates etc. The greater the distance from
the primary measurement to the overall result in a model, the
more difﬁcult threshold setting will become because of error
propagation.
Setting of thresholds or other means of deriving a test result
(data analysis procedure) is a most critical part of test
development. It determines the sensitivity and speciﬁcity of
the new test, that is, the proportion of false-positive and false-
negative results. Noteworthy, this needs to be done before
validation, but we already need a substantial ‘‘training set’’ of
substances to derive the data analysis procedure, that is, the
algorithm to convert raw experimental results into a test result
(positive/negative, highly toxic, moderate, mild...). This raises
the question, where such reference results come from?
CHALLENGE 4: WHAT TO VALIDATE AGAINST?
The ﬁrst problem is that the choice of the point of reference
determines where we will arrive. If the new toxicology is based
onanimaltestsasthereference,wecanonlyapproachthis‘‘gold
standard’’ but will not be able to overcome its shortcomings. We
havesuggested(Hoffmannetal.,2008)theconceptofcomposite
reference points, that is, a consensus process of identifying the
reference result attributed to a reference test substance. This
allows at least the investigator to review and revise individual
results,butdoesnotchangethemainproblemthatmostlyanimal
data are only available.
Thesecondproblemisthatitisunlikelythatwewillbeableto
evaluatetheentirepathway-basedteststrategyinonestep.Sothe
question becomes what to validate against, if we have only
partial substitutes? If we have the perfect test for a pathway of
toxicity, where are the data on substances to test against—we
will typically not know which of the many pathways was
triggered in vivo. As a way forward we have proposed
a ‘‘mechanistic’’ validation (Coecke et al., 2007), where it is
shown that the prototypic agents affecting a pathway are picked
up while others not expected to do so are not.
There are various challenges to the validation process as it is
right now (Hartung et al., 2004), which we have discussed
elsewhere (Ahr et al., 2008; Hartung, 2007a). Especially for the
complex omic technologies and other information-rich and
demanding technologies, we are only starting to see the
challenges for validation (Corvi et al., 2006).
CHALLENGE 5: HOW TO OPEN UP REGULATORS FOR
CHANGE?
We have coined the term ‘‘postvalidation’’ (Bottini et al.,
2008) to describe the cumbersome process of regulatory
acceptance and implementation. It is increasingly recognized
that it is neither the lack of new approaches nor their proven
reliability by validation, but that translation into regulatory
guidelines and use is now the bottle-neck of the process.
Change requires giving up on something not to add to it. As
long as most new approaches are considered ‘‘valuable
additional information,’’ the incentive to drive new approaches
through technical development, validation and acceptance is
ratherlow,given10–12yearsofworkoflargeteamsandcostsof
several hundred thousand dollars. The process is so demanding
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lute proof that a new method is equal to or better than traditional
approaches. Most importantly, to let go from tradition requires
seeing the limitations of what is done today. This discourse was
too long dominated by animal welfare considerations. This has
been convincing for parts of the general public, but the scientiﬁc
and regulatory arena is much less impressed by this argument.
Especially, if personal responsibility and liability come into
play, traditional tests are rarely abandoned. Costs are not too
much of an issue, because they are the same for competitors
and become simply part of the costs of the products. In general,
costs are less than 1%—often 0.1%—of the turnover of regu-
lated products (Bottini and Hartung, 2009). Thus, the major
driving force for change would be that we can do things better.
However, limitations are not very visible in this ﬁeld and the
interest to expose them is low. In order to identify limitations,
we would need, ﬁrst of all, transparency of data and decisions,
and establishment of reproducibility and relevance of our
approaches. Neither of this is given: data are typically not
published and/or are considered proprietary; repeat experi-
ments are often even excluded by law and data on the human
health effects are rare for comparison (Hartung, 2008a). This
leaves us in a situation, where ‘‘expertise,’’ that is, the opinion
of experts rules, whereas hard data (‘‘evidence’’) are short in
supply.
Interestingly, clinical medicine is in a similar situation, that
is, facing the coexistence of traditional and novel scientiﬁc
approaches. Here, however, information overload rather than
lack of data is the problem. A remarkable process has taken
place over the last two decades, which is called Evidence-based
Medicine (EBM). The Cochrane Collaboration includes more
than 16,000 physicians and has so far produced about 5000
systematic reviews compiling the available evidence for an
explicit medical question in a transparent and rigorous process.
Among others this has stimulated the development of meta-
analysis tools in order to combine systemically information
from various studies.
We (Hoffmann and Hartung, 2006) and others (Guzelian
et al., 2005) have put forward the idea to initiate a similar
process for toxicology. Consequently, the ﬁrst International
Forum toward and Evidence-based Toxicology (EBT) was held
in 2007 bringing together more than 170 stakeholders from
four continents (www.ebtox.org, Griesinger et al., in press).
Three main areas of interest emerged (1) a systematic review of
methods (similar to the review of diagnostic methods in EBM),
(2) the development of tools to quantitatively combine results
from different studies on the same or similar substances
(analogous to meta-analyses); and (3) the objective assessment
of causation of health as well as environmental effects. This
movement is still in its infancy. However, it promises to help
with a key obstacle, that is, identifying the limitations of
current approaches, and thus might be the door-opener for any
novel approach. Due to its transparency and rigor in approach,
judgments are likely more convincing than classical scientiﬁc
studies and reviews. At the same time, the objective
compilation of conclusions from existing evidence requires
the development of tools, which will have broader impact,
especially the meta-analysis type of methods or scoring tools for
data quality. The latter has been furthered as a direct outcome of
the EBT forum in a contract and expert consultation by the
European Centre for the Validation of Alternative Methods
(ECVAM) (Schneider et al., unpublished data). It aims to base
the well-known ‘‘Klimisch scores’’ (Klimisch et al., 1997) for
dataqualityonasystematicsetofcriteria,oneseteachforinvivo
and for in vitro data. This might have enormous impact for the
requested systematic use of existing data, for example, for the
European REACH registration process of existing chemicals.
It provides the means to include, reject or weigh existing
information before decisions on additional test needs are taken,
or for combined analysis.
With regard to the novel toxicological approaches, however,
most important will be that existing and new ways are assessed
with the same scrutiny. Sound science is the best basis for the
selection of tools. Validating against methods believed to do
aproperjobisonlybettingandwillalwaysintroduceuncertainty
about the compromise made while forgetting about the com-
promise represented by the traditional method.
The term of evidence-based toxicology must not be confused
with weight-of-evidence approaches, which describe an often
personal judgment of the different information available to
come to an overall conclusion, for example, in genotoxicity.
Such approaches have also been suggested in the validation
process (Balls et al., 2006), but they represent rather com-
promise solutions in the absence of ﬁnal proof. In contrast,
EBT aims to use all evidence reasonably available to come to
a judgment in a transparent and objective manner.
CHALLENGE 6: THE GLOBAL DIMENSION
A central obstacle for the introduction of new approaches is
globalization of markets. Globally acting companies want to use
internationally harmonized approaches. This means that change
to new approaches if not forced by legislation, will occur when
the last major economic region has agreed on the new one.
A teaching experience (Hartung, in press) was the Local Lymph
Node Assay (LLNA) in mice (notably an in vivo alternative
method) to replace guinea pig tests such as the Buehler and
guinea pig maximization test. Since 1999, the LLNA is the
preferred method in Europe reinforced by an animal welfare
legislation, which requests such reduction and reﬁnement
methods to be used whenever possible, and since 2001, the test
is OECD-accepted. Still, in 2008, we found that out of about
1450new chemicals registered with skin sensitization data since
1999 in Europe, only about 50 had LLNA data, whereas the rest
was still tested in the traditional tests. This illustrates the
resistance to change even when ‘‘only’’ exchanging one animal
test by another. We can imagine, how much more difﬁcult this
20 HARTUNGwill be for in vitro or in silico approaches, or the complex new
approaches aimed for now.
This means that efforts to create a novel approach need global
buy-in. National solutions will quickly encounter nontechnical
problems for implementation and acceptance. When lobbying
forprogramstoidentify pathways oftoxicity(ormoregeneral of
interaction ofsmallmolecules withcells) project,theaim should
beforaglobalprogramfromthestart,forexample,similartothe
human genome project.
We should, however, not be too negative about the impact
of globalization. As discussed earlier (Bottini et al., 2007), this
might as much constitute a driver for change as it is now an
obstacle. International harmonization is an opportunity to
export standards of safety assessments to trade partners (Bottini
and Hartung, 2009).
CHALLENGE 7: QUALITY ASSURANCE FOR THE NEW
APPROACH
For the global use of methods, it does not sufﬁce to agree on
how to test. If we want to accept approaches executed at other
places, challengeable quality standards for performance and
documentation of tests must exist, as they have been developed
as OECD Good Laboratory Practice (GLP) or various ISO
standards. GLP was, however, developed mainly for the
dominating in vivo tests. Building on a workshop to identify
the gaps for a GLP for in vitro approaches (Cooper-Hannan
et al., 1999), and the parallel development of Good Cell
Culture Practices (Coecke et al., 2005; Hartung et al., 2002),
now some OECD guidance for in vitro toxicology is available
(OECD, 2004). However, for the complex methods envisaged
for the new type of toxicity tests will require a much more
demanding quality assurance. We must learn how to report
properly the results from new methods like genomics or
QSARs—we have to imagine, how difﬁcult it will be to report
in a standardized manner the whole process. A key problem
will be the ﬂuid nature of the new methodologies: standard-
ization and validation requires freezing things in time, every
change of method requires re-evaluation not possible for the
complex methodologies. On the contrary, we see continuous
amendments of in silico models or new technologies (e.g., gene
chips). Shall we validate and implement a certain stage of
development and close the door for further developments? This
is exactly what is required for international agreements on
methods—and it is difﬁcult to imagine for complex methods
still under development.
CHALLENGE 8: HOW TO CHANGE WITH STEP BY STEP
DEVELOPMENTS BECOMING NOW AVAILABLE?
Things would be easy if a new regulatory toxicology would
become available at once—we might then compare old and new
and decide to change. But we will continue to receive bits and
pieces(Fig.1)aswehavealreadyexperiencedforawhile.When
should we make a major change and not just add and replace
patches? What is not clear is, where the mastermind for change
will come from. Which group or institution will lead us through
the change? Given the substantial efforts for the development of
each piece, we can not wait for their implementation until
everything is ready.
The ﬁrst of two solutions is to implement the new methods
in parallel to gain experience with the new without abandoning
the old. Beside the costs, this will create the problem of what to
do with discrepant information. Although we need this on the
one hand (or we will not result in something new), we will not
be able to neglect any indications of hazard from new tests (we
have lost our innocence), even though they have not yet taken
over. The second opportunity is to start with those areas where
we have new problems and explore the new opportunities. This
might include new health endpoints such as endocrine
disruption, developmental neurotoxicity, respiratory sensitiza-
tion or new products such as biologicals, genetically modiﬁed
organisms, nanoparticles, or cell therapies. But in both cases
we might fall into the trap of just adding new patches without
substantial change. This means we have to somehow to
organize a transition. Many people working at different angles
of the whole will not create the ‘‘new deal.’’
CHALLENGE 9: HOW TO ORGANIZE TRANSITION?
Beside the technological challenge, we have identiﬁed the
need for systematic combination of approaches (integrated
testing), and a program to assess objectively current approaches,
to validate them and to implement them. This program requires
out-of-the-box thinking, that is, intellectual steering (Fig. 2).
As a ﬁrst step, with the ﬁnancial support of the Doerenkamp-
Zbindenfoundation(http://www.doerenkamp.ch/en/)whichhave
been created in recent years ﬁve professorships for alternative
FIG. 1. The continuous process of development, integration and
acceptance of new methods.
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Utrecht,Geneva,andmostrecently,JohnsHopkinsinBaltimore).
Moreover, a Transatlantik Think Tank of Toxicology (T
4)w a s
created (ALTEX, 2008) between the toxicological chairs of these
institutions, which aims to collaborate on dedicated studies and
analyses, and workshops to support the paradigm shift in
toxicology.
Certainly this is only the ﬁrst little step, but it might form
a nucleus for further initiatives. Similarly, the Forum series in
Toxicological Sciences, and discussions at the SOT meetings,
furthers the shaping and sharpening of ideas.
CHALLENGE 10: MAKING IT AWIN/WIN/WIN SITUATION
Three major stakeholders will have to collaborate to create
the new toxicology, that is, the academia, regulators and the
regulated communities in industry. This collaboration is still
more an exception (for example the European Partnership for
Alternative Approaches (EPAA), between 40 companies, 7
trade associations, and the European Commission) than the rule
(Bottini and Hartung, 2009; Hartung, 2008c). Academia has
not been involved, although research funding and emerging
technologies may help to increase academic engagement. The
time for validation and acceptance of new methods of about
one decade make this area only of little attraction for academics,
andmostarenotinadialoguetherebyenablingthemtounderstand
the needs of industry and regulators. The exchange between
industry and regulators is also often poor, perhaps driven by
concern that providing more information is only giving more
opportunityforfurtherrequests.IntheUnitedStates,welackboth
the public/private partnership and the research funding into
alternative approaches. By basing the novel toxicology less on
animal welfare and more on sound science considerations, this
might change in the future. The shear dimensions of the tasks
ahead will require a trans-disciplinary, trans-national, trans-
stakeholder, and trans-industrial sectors approach. Information
hubs such as AltWeb (http://altweb.jhsph.edu/), AltTox (http://
www.alttox.org/), EPAA (http://ec.europa.eu/enterprise/epaa/),
EBTox (http://www.ebtox.org), ECVAM (http://ecvam.jrc.it/),
and the Center for Alternatives to Animal Testing (http://
caat.jhsph.edu/) have a key role here.
There is gain for all players including the following: the
challenge of the development of new approaches; the better
understanding of limitations of our assessments; the likely
development of safer products with new test approaches; and
the international harmonization prompted by a major joint
effort. There is economic gain as well (Bottini and Hartung,
2009), but while we are talking broadly about science, ethics
and politics, this has not been sufﬁciently addressed. The
stairway to ‘‘Regulatory Toxicology version 2.0’’ is steep, but
the goal merits the effort.
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